Recently, patients with colorectal cancer (CRC) indicates that EV-A71 is associated with immune-based anticancer therapy as EV-A71 inhibits tumor growth in nude mice CRC model by repressing Bcl-2 expression (Ruan et al., 2023). This evidence concerns the gene BCL2 and colorectal carcinoma.